EGFR

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.

Cat No.	product name
T0078	LapatinibHOT	Lapatinib is a dual inhibitor of Lapatinib is a dual ErbB2/EGFR (IC50: 9.2/10.8 nM) inhibitor
T0078L	Lapatinib ditosylate monohydrate	Lapatinib is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib therapy is associated with tra...
T0129	Sanguinarine chloride	Sanguinarine chloride, a benzophenanthridine alkaloid, stimulates apoptosis by activating the production of reactive oxygen species (ROS).
T0373	ErlotinibHOT	Erlotinib is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
T0373L	Erlotinib hydrochlorideHOT	Erlotinib is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
T0801	Tannic acid	Tannic acid is a novel hERG channel blocker.
T10256	Afatinib D6	Afatinib D6 (BIBW 2992 D6) is a deuterium-labeled Afatinib. Afatinib is an irreversible EGFR family inhibitor.
T10419	AV-412	AV-412 is an EGFR inhibitor (EGFR, EGFR T790M, EGFR L858R, EGFR L858R/T790M and ErbB2 with IC50s of 0.75, 0.79, 0.5, 2.3, 19 nM).
T10433	Osimertinib dimesylate	Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).
T10531	BGB-102	BGB-102 is a potent multi-kinase inhibitor against HER2, EGFR, and HER4 (IC50s: 18 nM, 9.6 nM, and 40.3 nM).
T10534	BI-4020	BI-4020 is a fourth-generation, non-covalent, and orally active inhibitor of EGFR tyrosine kinase.
T10556	BKI-1369	BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).
T10802	CHMFL-EGFR-202	CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
T10965	DBPR112	DBPR112 has an IC50 of 15 nM and 48 nM for EGFRWT and EGFRL858R / T790M, respectively. It is an oral active epidermal growth factor receptor inhibitor based on ...
T11157	EGFR-IN-1	EGFR-IN-1 displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity. EGFR-IN-1 is an orall...
T11157L	EGFR-IN-1 hydrochloride	EGFR-IN-1 hydrochloride displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity. EGFR-IN...
T11158	EGFR-IN-11	EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1.EGFR-IN-11 is a fourth-generation EGFR-tyrosi...
T11159	EGFR-IN-2	EGFR-IN-2 is a non-covalent, mutation-selective and irreversible second-generation EGFR inhibitor.
T11160	EGFR-IN-5	EGFR-IN-5 is a EGFR inhibitor, EGFR-IN-5 with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively.
T11161	EGFR-IN-7	EGFR-IN-7 is a selective and potent EGFR kinase inhibitor.
T11162	EGFR-IN-8	EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
T11163	EGFR-IN-9	EGFR-IN-9 has antitumor activity. EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kin...
T11164	EGFR mutant-IN-1	EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R/T790M/C797S mutant inhibitors with IC50 of 27.5 nM, which significant...
T11213	Epertinib hydrochloride	Epertinib hydrochloride shows potent antitumor activity. Epertinib hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibito...
T11213L	Epertinib	Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM). It displays a strong antitumor...
T1144L	Lidocaine Hydrochloride hydrate	Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.
T11569	HKI-357	HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK p...
T11717	JHU395	JHU395 delivers 6-diazo-5-oxo-L-norleucine (DON) to malignant peripheral nerve sheath tumor (MPNST) in vitro and in vivo, and has antitumor activity in MPNST. J...
T1181	GefitinibHOT	Gefitinib is an EGFR tyrosine kinase inhibitor and can inhibit Tyr1173, Tyr992, Tyr1173 and Tyr992 (IC50s: 37/37/26/57 nM).
T12130	Mutated EGFR-IN-2	Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.
T12131	Mutated EGFR-IN-3	Mutated EGFR-IN-3 is a ATP-competitive and highly selective allosteric dibenzodiazepinone EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) inhibitor(IC50 of 12 nM ...
T12175	Naquotinib mesylate	Naquotinib mesylate is an orally available, mutant-selective and irreversible inhibitor of EGFR(iC50s of 8-33 nM and 230 nM for toward EGFR mutants and EGFR).
T1266	Terfenadine	Terfenadine is a prodrug that is metabolized by intestinal CYP3A4 to the active form fexofenadine, a selective histamine H1-receptor antagonist with antihistami...
T12777	RTC-5	RTC-5 demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects we...
T1291	Cisapride	Cisapride is a serotonin type 4 (5-HT4) receptor agonists are potent prokinetic agents that act on serotonin receptors in the intestine and promote intestinal p...
T12912	Sigma-1 receptor antagonist 3	Sigma-1 receptor antagonist 3 is a potent and selective antagonist of Sigma-1 (σ1) receptor(Ki : 1.14 nM), has the potential for the neuropathic pain.
T13088	Tarloxotinib bromide	Tarloxotinib bromide is an irreversible inhibitor of EGFR/HER2.
T13559	Astragaloside VI	Astragaloside VI could improve wound healing by activating the EGFR/ERK signaling pathway.
T13743	JH-XI-10-02	JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19. JH-XI-10-02 is a potent and selective degrad...
T14138	AG-825	AG-825(Tyrphostin AG-825) is a potential agent for overcoming Mn-induced neurotoxicity or AD development[5] and is a selective and ATP-competitive ErbB2 inhibit...